The prognostic use of inflammation and tissue necrosis in benign prostatic hyperplasia

Urologia Internationalis

Volumn 91, Issue 1, 2013, Pages 19-25

  Willder, Jennifer M ^a,c   Walker, Victoria C ^a   Halbert, Gwen L ^b   Dick, Craig P C ^b   Orange, Clare ^b   Qayyum, Tahir ^a   Horgan, Paul G ^c   Underwood, Mark A ^d   Edwards, Joanne ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Benign prostatic hyperplasia; Inflammation; Lower urinary tract symptoms

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; AGE; AGED; ARTICLE; BLADDER CATHETERIZATION; DISEASE CLASSIFICATION; DRUG TREATMENT FAILURE; GLASGOW PROGNOSTIC SCORE; HISTOLOGY; HUMAN; INFLAMMATION; KLINTRUP MAKINEN CRITERIA; LOWER URINARY TRACT SYMPTOM; MALE; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE HYPERTROPHY; SCORING SYSTEM; SCOTTISH INDEX OF MULTIPLE DEPRIVATION; TISSUE NECROSIS; TISSUE NECROSIS SCORING SYSTEM; URINARY CATHETER;

AGED; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NECROSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC HYPERPLASIA; REGRESSION ANALYSIS;

EID: 84880921637     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000345907     Document Type: Article

References (31)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL: The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-479.
2. De Nunzio C, Kramer G, Marberger M, et al: The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 2011; 60: 106-117.
3. Rohrmann S, De Marzo AM, Smit E, Giovannucci E, Platz EA: Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate 2005; 62: 27-33.
4. Liao CH, Chung SD, Kuo HC: Serum C-reactive protein levels are associated with residual urgency symptoms in patients with benign prostatic hyperplasia after medical treatment. Urology 2011; 78: 1373-1378.
5. Kohnen PW, Drach GW: Patterns of inflammation in prostatic hyperplasia: A histologic and bacteriologic study. J Urol 1979; 121: 755-760.
6. Di Silverio F, Gentile V, De Matteis A, et al: Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: A retrospective analysis. Eur Urol 2003; 43: 164-175.
7. Castro P, Xia C, Gomez L, Lamb DJ, Ittmann M: Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia. Prostate 2004; 60: 153-159.
8. Royuela M, Ricote M, Parsons MS, Garcia-Tunon I, Paniagua R, de Miguel MP: Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplastic, and malignant human prostate. J Pathol 2004; 202: 41-49.
9. Tuncel A, Uzun B, Eruyar T, Karabulut E, Seckin S, Atan A: Do prostatic infarction, prostatic inflammation and prostate morphology play a role in acute urinary retention? Eur Urol 2005; 48: 277-283, discussion 283-284.
10. Choong S, Emberton M: Acute urinary retention. BJU Int 2000; 85: 186-201.
11. Qayyum T, McArdle PA, Going JJ, et al: Is the presence or absence of tumour necrosis a significant predictor of survival in renal cell cancer? Urol Int 2012; 88: 79-83.
12. Klintrup K, Makinen JM, Kauppila S, et al: Inflammation and prognosis in colorectal cancer. Eur J Cancer 2005; 41: 2645-2654.
13. Roxburgh CS, McMillan DC: Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010; 6: 149-163.
14. Shafique K, Proctor MJ, McMillan DC, Qureshi K, Leung H, Morrison DS: Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study. Prostate Cancer Prostatic Dis 2012; 15: 195-201.
15. Kramer G, Steiner GE, Handisurya A, et al: Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 2002; 52: 43-58.
16. Roxburgh CS, Salmond JM, Horgan PG, Oien KA, McMillan DC: Tumour inflammatory infiltrate predicts survival following curative resection for node-negative colorectal cancer. Eur J Cancer 2009; 45: 2138-2145.
17. Lamb AD, Qadan M, Roberts S, et al: CD4+ and CD8+ T-lymphocyte scores cannot reliably predict progression in patients with benign prostatic hyperplasia. BJU Int 2011; 108:E43-E50.
18. Robert G, Descazeaud A, Nicolaiew N, et al: Inflammation in benign prostatic hyperplasia: A 282 patients' immunohistochemical analysis. Prostate 2009; 69: 1774-1780.
19. Schenk JM, Kristal AR, Neuhouser ML, et al: Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol 2012; 171: 571-582.
20. St Sauver JL, Sarma AV, Jacobson DJ, et al: Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a populationbased cohort. Am J Epidemiol 2009; 169: 1281-1290.
21. Koenig W, Sund M, Frohlich M, et al: C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middleaged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-242.
22. Anjum I, Ahmed M, Azzopardi A, Mufti GR: Prostatic infarction/infection in acute urinary retention secondary to benign prostatic hyperplasia. J Urol 1998; 160: 792-793.
23. Jacobsen SJ, Jacobson DJ, Girman CJ, et al: Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997; 158: 481-487.
24. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H: An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002; 168: 2395-2400.
25. Leibovich BC, Blute ML, Cheville JC, et al: Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: A stratification tool for prospective clinical trials. Cancer 2003; 97: 1663-1671.
26. Klatte T, Said JW, de Martino M, et al: Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification. J Urol 2009; 181: 1558-1564.
27. Spiro LH, Labay G, Orkin LA: Prostatic infarction. Role in acute urinary retention. Urology 1974; 3: 345-347.
28. Baird HH, McKay HW, Kimmelstiel P: Ischemic infarction of the prostate gland. South Med J 1950; 43: 234-240.
29. Abeshouse BS: Infarct of the prostate. J Urol 1933; 30: 97.
30. Strachan JR, Corbishley CM, Shearer RJ: Post-operative retention associated with acute prostatic infarction. Br J Urol 1993; 72: 311-313.
31. Jones TJ, Howie AJ: Necropsy study of infarcts of prostate and prostatic urethra. J Clin Pathol 1986; 39: 1221-1223.